Author:
Kucharz Jakub,Giza Agnieszka,Dumnicka Paulina,Kuzniewski Marek,Kusnierz-Cabala Beata,Bryniarski Pawel,Herman Roma,Zygulska Aneta Lidia,Krzemieniecki Krzysztof
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference20 articles.
1. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884–96.
2. Escudier B, Porta C, Schmidinger M, ESMO GuidelinesWorking Group, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii49–56.
3. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–63.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
5. Kucharz J, Michalowska-Kaczmarczyk A, Streb J, et al. The changes in complete blood count in patients treated with sunitinib malate for metastatic clear cell renal cell carcinoma. Prz Lekarski. 2013;70:712–4.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献